Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer by unknown
RESEARCH Open Access
Local efficacy and survival outcome of
salvage endoscopic therapy for local
recurrent lesions after definitive
chemoradiotherapy for esophageal cancer
Ken Hatogai1,2,3, Tomonori Yano1*, Takashi Kojima2, Masakatsu Onozawa4, Satoshi Fujii5, Hiroyuki Daiko6,
Yusuke Yoda1, Takuya Hombu1, Toshihiko Doi2, Kazuhiro Kaneko1 and Atsushi Ohtsu2,7
Abstract
Background: Salvage endoscopic therapy (SET), such as endoscopic mucosal resection (EMR) and photodynamic
therapy (PDT), is a less-invasive treatment for local failure at the primary site after chemoradiotherapy (CRT) for
esophageal squamous cell carcinoma (ESCC). We conducted this retrospective study to clarify the risk factors for
local recurrence along with the long term results after SET for recurrent lesions after definitive CRT for ESCC.
Methods: We enrolled 77 consecutive patients who underwent EMR or PDT for local recurrence without any
metastasis after definitive CRT at our institution. We evaluated the local efficacy, local recurrence-free survival (LRFS),
and overall survival (OS), and investigated the risk factors associated with survival outcome using a multivariate
analysis.
Results: The complete resection rate of EMR was 84.6 % (33/39), and the complete response rate for PDT was
65.8 % (25/38). Twenty-two patients (28.6 %) exhibited local recurrence without metastasis. Thirty-four patients
(44.2 %) were alive at 5 years after undergoing only initial SET or with repeated SET. The 5-year LRFS rate was
59.6 %, and the presence of lesions occupying an esophageal circumference of 1/4 or larger was the only
significant risk factor (HR: 3.10, 95 % CI: 1.35–7.15, P = 0.008). The 5-year OS rate was 48.4 %, and an advanced T
factor before CRT was marginally associated with a poor OS (HR: 1.96, 95 % CI: 0.98–3.92, P = 0.055).
Conclusions: SET enabled a preferable local control and survival outcome for patients with local recurrence after
definitive CRT for ESCC. Careful endoscopic follow-up is needed for patients with a large lesion before SET and
those with an advanced T factor before CRT.
Keywords: Photodynamic therapy, Endoscopic mucosal resection, Chemoradiotherapy, Salvage treatment,
Esophageal cancer, Local recurrence
Introduction
Concurrent chemoradiotherapy (CRT) is a definitive
treatment option for locally advanced esophageal squa-
mous cell carcinoma (ESCC) [1, 2]. Even if a complete
response is achieved, locoregional recurrence often oc-
curs and is a major obstacle to achieving a cure [3–5].
According to the current National Comprehensive
Cancer Network guideline, an esophagectomy can be
proposed for patients with locoregional recurrence if the
lesion is resectable and the patient is medically operable,
while chemotherapy or palliative care should be pro-
posed if the lesion is not resectable or if the patient is
not medically operable [6]. However, an esophagectomy
following definitive CRT is associated with a higher inci-
dence of postoperative adverse events and mortality,
compared with both primary surgery and planned sur-
gery after neoadjuvant CRT [7–10]. Therefore, no estab-
lished standard therapy exists for relatively shallow
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recurrent lesions limited to the esophagus. Reportedly,
patients who have achieved a complete response with
CRT are very unlikely to experience a recurrence at
locoregional lymph nodes [11]. In patients with local re-
currence at the primary site and without any recurrence
in the lymph nodes, only treatment for the local recurrent
lesion is capable of achieving a cure. Given the importance
of local control at the primary site and the possible ad-
verse events related to salvage surgery, salvage treatment
at the primary site using endoscopy could be a curative
and less invasive option in select patients.
We have performed two kinds of salvage endoscopic
therapy (SET), endoscopic mucosal resection (EMR) and
photodynamic therapy (PDT), as optional treatments for
local failure (such as local residual lesions after CRT and
local recurrent lesions after the achievement of a complete
response after CRT) and have reported favorable efficacy
and safety results for each treatment [12, 13]. Further-
more, local recurrent lesions were thought to be good
candidates for SET [13]. While EMR is relatively concise
and is a widely used procedure, it is only indicated for le-
sions within the shallow submucosal layer. In contrast,
PDT can be used for lesions that have invaded even the
muscularis propria layer; however, this technique is associ-
ated with phototoxicity requiring a long period of avoiding
sunlight. The significance of SET is its ability to cure the
local recurrent lesion while allowing organ preservation.
However, patients undergoing SET often experience local
recurrence after the initial SET, and some of these patients
can be rescued by an additional SET. If the risk factors for
local recurrence are clarified, intensive endoscopic obser-
vations could be performed for patients with a high risk.
To date, no study has integrated these treatment out-
comes in a comprehensive assessment. The aim of the
present study was to clarify the risk factors for local recur-
rence after SET along with the long-term results of SET
after definitive CRT for ESCC.
Patients and methods
Patients
We enrolled consecutive patients with a local recurrent
lesion who underwent SET at the National Cancer Center
Hospital East in this retrospective study according to the
following selection criteria among patients who under-
went definitive CRT for ESCC at the National Cancer
Center Hospital East between 1998 and 2008 and patients
referred from other hospitals for salvage treatment after
definitive CRT during the same period: 1) received defini-
tive CRT prior to SET, which consisted of external beam
irradiation of 50 Gy or more along with chemotherapy;
and 2) absence of any lymph node or distant metastasis as
determined using computed tomography (CT) before
SET. The study protocol was approved by the institutional
review board of the National Cancer Center Hospital East
(2012–275). The study was carried out according to the
ethical principles of the Declaration of Helsinki and the
Epidemiological Study Guideline of Ministry of Health,
Labour and Welfare in Japan. For the deceased patients
and their relatives, we disclosed the study design on the
website of the National Cancer Center and gave them the
opportunity to refuse participation in this retrospective
study.
Evaluation before CRT and SET
Clinical staging before CRT was determined by endos-
copy, endoscopic ultrasound (EUS), and contrast en-
hanced CT according to the TNM Classification of the
International Union Against Cancer [14]. Positron emis-
sion tomography was an option before CRT and before
SET. All the patients underwent endoscopy and contrast
CT after the completion of CRT to evaluate the response.
A complete response after CRT was determined when an
endoscopic examination showed the disappearance of the
primary tumor and the absence of cancer cells in biopsy
specimens, in addition to the achievement of a complete
response according to the Response Evaluation Criteria in
Solid Tumors on a CT scan [15].
Local recurrent lesions were defined as follows: 1) re-
currence after having once achieved a complete response
after CRT, in the area where the primary tumor had
existed prior to CRT; and 2) biopsy findings were posi-
tive for cancer cells from the recurrent lesions. Before
SET, all the patients were evaluated and staged using
EUS (EU-M2000; Olympus Co. Ltd., Tokyo, Japan) with
a high-frequency (20 MHz) ultrasound probe. Lesions
were classified as either uT1 (limited to the submucosal
layer) or uT2 (limited to the muscularis propria layer)
[16]. The lesion circumference was classified as follows
based on Lugol’s chromoendoscopy and EUS findings:
<1/4; ≥1/4 and <1/2; ≥1/2 and <3/4; ≥3/4.
Indications for salvage endoscopic therapy and criteria
for treatment choice
The indications for SET were as follows: 1) local recur-
rence limited to within uT2, as determined using EUS
and CT; 2) the absence of lymph node or distant organ
metastasis when a local recurrence was detected; and 3)
patients’ refusal to undergo salvage surgery or a physical
condition that would have made surgery intolerable.
Since PDT requires an approximately 4-week period of
no exposure to sunlight after the administration of a
photosensitizer, EMR was typically chosen for SET for
local recurrence because of convenience if the lesion ful-
filled the following criteria: 1) absence of ulceration on
the lesion, and 2) limited to the shallow submucosal
layer as determined using EUS. If ulceration or fibrosis
was present in the lesions or the depth of the lesion was
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suspected to be the deep submucosal layer or deeper,
PDT was indicated for SET.
Procedures
The technique used for salvage EMR consisted of the
strip biopsy method [17]. Briefly, after the submucosal
injection of saline solution, EMR was performed using a
dual channel endoscope (2 T240; Olympus, Tokyo,
Japan). The resected specimens were pathologically eval-
uated by experienced pathologists. A complete resection
was determined based on both clinical and pathological
evaluations. For the clinical evaluation, the edge of the
post-EMR ulcer was carefully assessed using Lugol’s
chromoendoscopy just after EMR; if the unstained area
had been completely removed, a clinically complete re-
section was defined. For the pathological evaluation, a
complete resection after EMR with en bloc resection
was defined when cancer cells were not observed at the
horizontal and vertical resection margins of the speci-
mens when examined microscopically. For EMR with a
piecemeal resection, a complete resection was defined
when cancer cells were not observed at the supposed
resection margin after the resected pieces had been
reconstructed. In this study, a complete resection was
required to have fulfilled both the clinical and patho-
logical definitions.
PDT was performed using an excimer dye laser (EDL-1;
Hamamatsu Photonics, Hamamatsu, Japan), as previously
reported [13]. Briefly, the procedure was initiated with the
intravenous administration of a photosensitizer, porfimer
sodium (Pfizer Japan Inc., Tokyo, Japan), followed by 630-
nm-wavelength excimer dye laser irradiation 48 h later.
We routinely performed an endoscopy on the following
day, and if an obvious residual tumor was found, an add-
itional laser irradiation was performed. A complete re-
sponse was regarded as the disappearance of the tumor
lesion and ulceration after PDT, as verified by endoscopic
examination, and the absence of cancer cells in the biopsy
specimens. In all the cases, the EMR and PDT procedures
were performed by 3 doctors certified by the Japan
Gastroenterological Endoscopy Society (TY, TK, and YY).
Representative images of patients who underwent EMR
and PDT are presented in Additional file 1: Figure S1 and
Additional file 2: Figure S2, respectively.
A follow-up examination consisting of endoscopy and
CT was performed to search for local recurrence and
lymph node or distant organ metastases every 3 months
for the first 2 years after SET and every 6 months
thereafter.
Statistical analysis
Differences in the patient characteristics were analyzed
using the t-test for continuous variables and the chi-
square test and the Fisher exact test for categorical
variables. To assess the local efficacy, the complete re-
section rate for EMR and the complete response rate for
PDT were evaluated and the confidence intervals (CI)
were obtained using the Clopper-Pearson method, then
compared using the Fisher exact test.
Two survival outcomes were measured: local
recurrence-free survival (LRFS) and overall survival (OS).
LRFS was defined as the period from the date of the initial
SET until the first date of the detection of histologically
confirmed local recurrence, and patients were censored at
the time of the last endoscopy if they showed no local re-
currence. OS was defined as the period from the date of
the initial SET until the date of death from any cause, and
patients were censored at the time of their last follow-up
if they were alive. Survival curves were estimated using
the Kaplan-Meier method and were compared using the
log-rank test. Univariate and multivariate Cox propor-
tional hazard models were used to examine the effect of
clinical factors on LRFS and OS. All the statistical analyses
were performed using IBM SPSS statistics 20 (IBM Japan
Ltd., Tokyo, Japan). All the P values were reported as two-
sided, with a significance level of 0.05.
Results
Patient characteristics
A total of 77 consecutive patients who had been treated
with SET for local recurrence after CRT were enrolled in
this study (Table 1). At the baseline before CRT, most of
the patients had T1-T3 disease; however, seven patients
with T4 disease were also included. Thirty patients
(39 %) had lymph node metastases, and 7 (9.1 %) of
them had non-regional lymph node metastases and were
evaluated as having Stage IV disease at baseline. None of
the patients in this study had distant organ metastasis
prior to undergoing CRT. Most of the patients received
a combination of cisplatin and fluoropyrimidine deriva-
tives with concurrent radiotherapy of 50.4 Gy or 60 Gy.
At SET, the median age of the patients at the time of
SET was 65 years, and the patients who underwent PDT
were significantly older than those who underwent EMR
(63.0 vs. 66.7, P = 0.038). Regarding the lesions before
SET, ten patients (26.3 %) had a uT2 lesion in the PDT
subgroup, and more patients had lesions with a larger
circumference than those observed in the EMR subgroup.
Local efficacy after SET
The local efficacy of SET is shown in Table 2. Among
the patients who underwent EMR, a complete resection
was achieved in 33 of the 39 patients, resulting in a
complete resection rate of 84.6 % (95 % CI: 69.5–94.1).
Among the six patients who did not achieve a complete
resection after EMR, two patients had a positive hori-
zontal margin, two patients had a positive vertical mar-
gin, and two patients had positive horizontal and vertical
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Table 1 Baseline characteristics before chemoradiotherapy and salvage endoscopic therapy
Before chemoradiotherapy Total (n = 77) EMR (n = 39) PDT (n = 38) P value
Characteristics Number % Number % Number %
Gender 1.000
Male 74 96.1 37 94.9 37 97.4
Female 3 3.9 2 5.1 1 2.6
Location 0.509
Upper 22 28.6 11 28.2 11 28.9
Middle 41 53.2 19 48.7 22 57.9
Lower 14 18.2 9 23.1 5 13.2
cT factor 0.271
1 33 42.9 21 53.8 12 31.6
2 10 13.0 4 10.3 6 15.8
3 27 35.1 11 28.2 16 42.1
4 7 9.1 3 7.7 4 10.5
Lymph node metastasis 0.355
Absent 47 61.0 26 66.7 21 55.3
Present 30 39.0 13 33.3 17 44.7
cStage 0.394
I 27 35.1 17 43.6 10 26.3
II 27 35.1 13 33.3 14 36.8
III 16 20.8 6 15.4 10 26.3
IV 7 9.1 3 7.7 4 10.5
Before salvage endoscopic therapy Total (n = 77) EMR (n = 39) PDT (n = 38) P value
Characteristics Number % Number % Number %
Median age (range) 65 (44–84) 63 (44–77) 67 (51–84) 0.038
Chemotherapy regimen 0.716
Cisplatin + fluoropyrimidine 71 92.2 36 92.3 35 92.1
Nedaplatin + fluoropyrimidine 3 3.9 2 5.1 1 2.6
Monotherapy 3 3.9 1 2.6 2 5.3
Radiation dose 0.702
50.4 29 37.7 13 33.3 16 42.1
60 43 55.8 23 59.0 20 52.6
> 60 5 6.5 3 7.7 2 5.3
Tumor depth evaluated with EUS <0.001
uT1 67 87.0 39 100.0 28 73.7
uT2 10 13.0 0 0.0 10 26.3
Circumferential spread 0.002
< 1/4 45 58.4 30 76.9 15 39.5
1/4 ≤, < 1/2 27 27.0 6 15.4 21 55.3
1/2 ≤, < 3/4 4 4.0 2 5.1 2 5.3
3/4 ≤ 1 1.3 1 2.6 0 0.0
Abbreviations: EUS endoscopic ultrasound, EMR endoscopic mucosal resection, PDT photodynamic therapy
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margins. Among the 13 patients who did not achieve a
complete response after PDT, cancer cells were patho-
logically detected in the biopsy specimens soon after
PDT in 12 of them, and one patient experienced a
treatment-related death (described later). Although the
complete resection rate for lesions occupying an esopha-
geal circumference smaller than 1/4 was higher than
those occupying an esophageal circumference of 1/4 or
larger, the difference was not significant (90.0 % vs.
66.7 %, P = 0.089).
Among the patients who underwent PDT, a complete
response was achieved in 25 of the 38 patients, resulting in
a complete response rate of 65.8 % (95 % CI: 48.6–80.4).
Although the complete response rate of patients with uT1
lesions was higher than that of patients with uT2 lesions,
the difference was not significant (71.4 % vs. 50.0 %, P =
0.263). Similarly, although the complete response rate of
lesions occupying an esophageal circumference smaller
than 1/4 was higher than that of lesions occupying an
esophageal circumference of 1/4 or larger, the difference
was not significant (80.0 % vs. 56.5 %, P = 0.136).
Clinical course after SET
The median follow-up time of the censored patients was
6.7 years (range, 1.6–14.1 years) from the date of SET.
The clinical course up to 5 years after initial SET is
shown in Fig. 1. A total of 39 patients did not develop
any recurrence, and 27 of them were alive at 5 years
after the initial SET. A total of 37 patients developed re-
currence at any site after SET, and local recurrence with-
out any metastasis was detected in 22 of these patients:
7 after EMR, and 15 after PDT. Among them, 18 pa-
tients underwent additional salvage therapy with curative
intent. Seven patients who consented to undergo surgery
underwent salvage esophagectomy, and 11 patients who
did not consent to undergo surgery underwent add-
itional SET according to the same indication criteria as
those used for the initial SET. In contrast, four patients
who were assessed as not being capable of tolerating sur-
gery and who did not fulfill the indication criteria for
SET received chemotherapy with palliative intent or
best-supportive care. Among 11 patients who underwent
additional SET, seven were alive at 5 years after the ini-
tial SET. Overall, 34 of the 77 patients (44.2 %) recruited
in this study survived for 5 years or longer after receiv-
ing only local treatment with SET. In addition to the
seven patients with local recurrence, five patients with
lymph node metastasis after SET underwent an esopha-
gectomy with lymph node dissection and one patient
with lung metastasis underwent a partial pneumonec-
tomy. As a serious toxicity, one patient in this series
who underwent PDT died as a result of a massive
gastrointestinal hemorrhage caused by esophageal-aortic
fistula formation that was possibly related to PDT.
In an analysis of the association between the resection
margin and local recurrence in patients undergoing
EMR, one of the six patients who had not achieved a
complete resection and 11 of the 33 patients who had
achieved a complete resection experienced a local
recurrence.
Survival outcomes after SET
The 5-year LRFS rates of patients undergoing EMR,
PDT, and all of the recruited patients were 66.7 % (95 %
CI: 50.2–83.2), 51.7 % (95 % CI: 33.7–69.7), and 59.6 %
(95 % CI: 47.4–71.8), respectively. The 5-year LRFS rate
of patients with cT1-2 lesions was higher than that of
patients with cT3-4 lesions, but the difference was not
significant (67.2 % vs. 50.2 %, P = 0.065 [log-rank test]).
The 5-year LRFS rate of patients with uT1 lesions was
Table 2 Local efficacy rate of salvage endoscopic therapy
Endoscopic mucosal resection Total Number Complete resection rate (%) 95 % CI P value
All patients 39 33 84.6 69.5–94.1
Circumference 0.089
< 1/4 30 27 90.0 73.5–97.9
1/4 ≤ 9 6 66.7 29.9–92.5
Photodynamic therapy Total Number Complete response rate (%) 95 % CI P value
All patients 38 25 65.8 48.6–80.4
uT factor 0.263
uT1 28 20 71.4 51.3–86.8
uT2 10 5 50.0 18.7–81.3
Circumferential spread 0.136
< 1/4 15 12 80.0 51.9–95.7
1/4 ≤ 23 13 56.5 30.6–73.2
Abbreviations: EMR endoscopic mucosal resection, PDT photodynamic therapy, CI confidence interval
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higher than that of patients with uT2 lesions, but the
difference was not significant (62.2 % vs. 50.0 %, P =
0.062 [log-rank test]). The 5-year LRFS rate of patients
with lesions occupying an esophageal circumference
smaller than 1/4 was significantly higher than that of
patients with lesions occupying an esophageal circumfer-
ence of 1/4 or larger (73.5 % vs. 38.3 %, P = 0.001 [log-
rank test]) (Fig. 2). In both univariate and multivariate
Cox proportional hazard models, circumferential spread
(1/4 or larger) was the only significant prognostic factor
for local recurrence after SET (hazard ratio [HR]: 3.10,
95 % CI: 1.35–7.15, P = 0.008) (Table 3).
The 5-year OS rates of patients undergoing EMR,
PDT, and all of the recruited patients were 55.0 % (95 %
CI: 38.9–71.1), 41.6 % (95 % CI: 25.7–57.5), and 48.4 %
(95 % CI: 37.0–59.8), respectively. The 5-year OS rate of
patients with cT1-2 lesions was significantly higher than
that of patients with cT3-4 lesions (59.5 % vs. 34.7 %, P =
0.018 [log-rank test]). The 5-year OS rate of patients with
uT1 lesions was significantly higher than that of patients
with uT2 lesions (54.3 % vs. 10.0 %, P = 0.002 [log-rank
test]). Though the 5-year OS rate of patients with lesions
occupying an esophageal circumference smaller than
1/4 was higher than those with lesions occupying an
esophageal circumference of 1/4 or larger, the differ-
ence was not significant (54.2 % vs. 40.4 %, P = 0.108
[log-rank test]) (Fig. 3). In a univariate Cox proportional
hazard model, the cT factor (T3-4) and uT factor (uT2)
were significant predictors of a poor OS. Although the cT
factor demonstrated a tendency toward an association
with a poor OS in a multivariate Cox proportional hazard
model, the correlation was not statistically significant (HR:
1.96, 95 % CI: 0.98–3.92, P = 0.055) (Table 3).
Discussion
In this study, we demonstrated that endoscopic inter-
ventions such as EMR and PDT are effective salvage
treatment strategies for local recurrence after definitive
CRT for ESCC, based on detailed data obtained over a
long follow-up period. We also showed that a large cir-
cumferential spread before SET was a risk factor for
local recurrence after SET, and lesions with an advanced
T factor before CRT were likely to be associated with a
shorter OS. We evaluated LRFS as the other survival
endpoint in addition to OS in the present study, al-
though to date local recurrence has not been confirmed
as a surrogate marker for OS. However, local recurrence
is a serious clinical event in patients with lymph node or
Fig. 1 Clinical course up to 5 years after salvage endoscopic therapy
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distant metastasis, since quality of life, represented by
oral intake, can be maintained if local control is
achieved. The 5-year OS rates were relatively higher
than those in our previous reports on both salvage EMR
and PDT [12, 13]. These higher values were likely
obtained because we recruited only patients with local
recurrence who had previously achieved a complete re-
sponse with definitive CRT and who were unlikely to ex-
perience recurrence in locoregional lymph nodes.
More than 40 % of the patients recruited in this study
survived for 5 years or longer with only repeated SET,
even if a local recurrence occurred after the initial SET.
Several prospective studies of definitive chemoradiother-
apy have demonstrated that failure in locoregional
lymph nodes occurred much less frequently than local
failure at the primary site, regardless of residue or recur-
rence [1, 18, 19]. In addition, Onozawa reported that
patients with a complete response after CRT rarely ex-
perience recurrence in locoregional lymph nodes [11].
The results of the present study supported the import-
ance of control for local recurrence after definitive CRT
and showed that a certain proportion of patients who
did not need salvage surgery were included in this popu-
lation. SET might be a treatment option for local recur-
rence after definitive CRT, especially for patients who
are unable to undergo surgery because of their poor
medical condition.
When EMR was performed as an initial treatment for
primary superficial ESCC, lesions with a large circumfer-
ential spread were associated with a positive resection
margin and local recurrence [20, 21]. The elevated risk
for local recurrence in patients undergoing SET for le-
sions with a large circumferential spread demonstrated
in the present study was in agreement with the situation
for initial EMR. However, local recurrence occurred rela-
tively frequently, even in patients who achieved a
complete resection with salvage EMR. In general, a local
recurrent lesion arises from part of a primary lesion.
Therefore, another recurrent lesion can arise later from
the same primary lesion as a result of metachronous
multifocal recurrence even if a complete resection of the
initial recurrent lesion is achieved by salvage EMR. Care-
ful endoscopic follow-up examinations are needed after
initial SET, keeping the possible existence of occult re-
current lesions in mind. Regarding OS, an advanced cT
factor before CRT and uT factor before SET seemed to
be associated with a poor OS, though the correlations
were not statistically significant. An advanced T factor
before CRT has also been shown to be a poor prognostic
factor in patients undergoing salvage surgery [7, 8, 22].
Considering that a significant proportion of patients
who initially showed an advanced T factor before CRT
obtained a long-term survival in the present study, such
patients may be candidates for SET. In contrast, PDT
Fig. 2 Local recurrence-free survival after salvage endoscopic therapy. a procedures. b cT factor before chemoradiotherapy. c uT factor before
salvage endoscopic therapy. d circumferential spread before salvage endoscopic therapy
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was indicated for the treatment of uT1 and uT2 local
failure lesions after CRT in clinical practice and in two
separate prospective Japanese PDT studies [23, 24].
However, given the poor OS of the patients with uT2 le-
sions, the survival benefit of SET, namely, PDT is sug-
gested to be small for those patients. The OS curve for a
surgical cohort of patients with a local recurrent lesion
of T1-2N0M0 disease after definitive CRT who under-
went salvage surgery during the same time period is
shown in Additional file 3: Figure S3. Although the 5-
year OS rate was lower than that of the PDT cohort, we
cannot make a simple comparison between the PDT co-
hort and the surgical cohort, given the small sample size
and the underlying selection biases.
Although the long-term efficacy of SET in patients
with local recurrence after definitive CRT has not been
previously evaluated, an important limitation of the
present study was that it was a single-institutional, retro-
spective study with a relatively small sample size. A pro-
spective, multi-institutional observational study is needed
to validate the presently reported results. Furthermore,
the diagnostic accuracy of EUS is limited because of
Table 3 Univariate and Multivariate Cox proportional hazard analyses
Characteristic Number Univariate Multivariate
HR 95 % CI P value HR 95 % CI P value
Local recurrence-free survival
Location
Upper 22 ref ref
Middle-Lower 55 0.95 0.41–2.16 0.894 1.13 0.49–2.60 0.777
cT factor
1–2 43 ref ref
3–4 34 2.01 0.94–4.32 0.072 1.89 0.87–4.12 0.107
uT factor
1 67 ref ref
2 10 2.55 0.95–6.86 0.065 1.21 0.42–3.46 0.725
Circumferential spread
< 1/4 45 ref ref
1/4 ≤ 32 3.38 1.54–7.41 0.002 3.10 1.35–7.15 0.008
Overall survival
age
≤ 65 39 ref ref
> 65 38 1.20 0.67–2.16 0.540 1.44 0.77–2.68 0.250
Location
Upper 22 ref ref
Middle-Lower 55 0.91 0.48–1.74 0.779 1.14 0.57–2.28 0.721
cT factor
1–2 43 ref ref
3–4 34 2.01 1.12–3.62 0.020 1.96 0.98–3.92 0.055
Lymph node metastasis
Absent 47 ref ref
Present 30 1.59 0.88–2.88 0.123 1.14 0.58–2.27 0.701
uT factor
1 67 ref ref
2 10 3.02 1.43–6.40 0.004 2.15 0.89–5.21 0.089
Circumferential spread
< 1/4 45 ref ref
1/4 ≤ 32 1.62 0.90–2.90 0.108 1.30 0.66–2.55 0.447
Abbreviations: HR hazard ratio, CI confidence interval
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radiation-induced esophagitis and ulceration when per-
formed soon after CRT [25]. In the present study, we only
performed EUS for patients with a recurrent lesion after a
complete response after CRT had been achieved and
radiation-induced esophagitis or ulceration had disap-
peared. In addition, we previously demonstrated a high
diagnostic accuracy of EUS for uT1 recurrent lesions after
definitive CRT using a different cohort that underwent
salvage EMR [26]. Although no diagnostic criteria for EUS
in this setting have been established to date, the diagnosis
of tumor depth using EUS may have been appropriate in
the present study.
Recently, endoscopic submucosal dissection (ESD) has
been applied as SET [27–29]. Not only may salvage ESD
enable the performance of an en block resection, but it
also may expand the indications for endoscopic resec-
tion for lesions that are not technically indicated for
EMR because of their size or the presence of fibrosis. Al-
though ESD as a treatment for primary superficial ESCC
can enable an en block resection and reduce local recur-
rence [30–32], whether ESD as SET can demonstrate a
similar efficacy has not been clarified. The accumulation
of data on patients undergoing ESD as SET is also needed.
Conclusions
In conclusion, we demonstrated the long-term efficacy
of SET for local recurrence after definitive CRT for
ESCC in an analysis of data obtained over a long follow-
up period. SET can be a treatment option for definitive
salvage treatment with appropriate patient selection
through a comprehensive assessment of both the primary
lesion before CRT and the recurrent lesion. Especially,
careful endoscopic follow-up is needed in patients with
large lesions before SET and before CRT, even if the local
recurrent lesions are found to have been cured with SET.
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Abbreviations
CI: confidence intervals; CRT: chemoradiotherapy; CT: computed tomography;
EMR: endoscopic mucosal resection; ESCC: esophageal squamous cell
carcinoma; ESD: endoscopic submucosal dissection; EUS: endoscopic
ultrasound; HR: hazard ratio; LRFS: local recurrence-free survival; OS: overall
survival; PDT: photodynamic therapy; SET: salvage endoscopic therapy.
Competing interests
The authors declare that they have no competing interests.
Fig. 3 Overall survival after salvage endoscopic therapy. a procedures. b cT factor before chemoradiotherapy. c uT factor before salvage endoscopic
therapy. d circumferential spread before salvage endoscopic therapy
Hatogai et al. Radiation Oncology  (2016) 11:31 Page 9 of 10
Authors’ contributions
KH and YT conceived and designed the study. KH, TY, TK, MO, SF, HD, YY, TH,
and TD acquired the data. KH, TY, TK, and MO analyzed and interpreted the
data. KH ant TY performed statistical analysis. KH and YT drafted the
manuscript. KH, TY, TK, MO, SF, HD, YY, TH, TD, KK, and AO reviewed and
revised the manuscript. All authors read and approved the final manuscript.
Acknowledgement
We thank Mr. Shogo Nomura for statistical advice.
Author details
1Department of Gastroenterology, Endoscopy Division, National Cancer
Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
2Department of Gastroenterology, Gastrointestinal Oncology division,
National Cancer Center Hospital East, Kashiwa, Chiba, Japan. 3Department of
Medical Oncology, Graduate School of Medicine, Chiba University, Chuo-ku,
Chiba, Japan. 4Department of Radiation Oncology, National Cancer Center
Hospital East, Kashiwa, Chiba, Japan. 5Division of Pathology, Exploratory
Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa,
Chiba, Japan. 6Department of Esophageal Surgery, National Cancer Center
Hospital East, Kashiwa, Chiba, Japan. 7Exploratory Oncology Research &
Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
Received: 16 November 2015 Accepted: 18 February 2016
References
1. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al.
INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of
combined-modality therapy for esophageal cancer: high-dose versus
standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–74.
2. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma.
Lancet. 2013;381:400–12.
3. Kato H, Sato A, Fukuda H, Kagami Y, Udagawa H, Togo A, et al. A phase II
trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma:
Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol. 2009;39:
638–43.
4. Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, et al. Phase II study
of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III
esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat
Oncol Biol Phys. 2011;81:684–90.
5. Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, et al. Definitive
chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma
of the esophagus. J Clin Oncol. 1999;17:2915–21.
6. National Comprehensive Cancer Network. Esophageal and Esohagogastric
Junction Cancers (Version 3. 2015). Available from URL: http://www.
nccn.org/professionals/physician_gls/pdf/esophageal.pdf
7. Chao YK, Chan SC, Chang HK, Liu YH, Wu YC, Hsieh MJ, et al. Salvage
surgery after failed chemoradiotherapy in squamous cell carcinoma of the
esophagus. Ejsxo. 2009;35:289–94.
8. Miyata H, Yamasaki M, Takiguchi S, Nakajima K, Fujiwara Y, Nishida T, et al.
Salvage esophagectomy after definitive chemoradiotherapy for thoracic
esophageal cancer. J Surg Oncol. 2009;100:442–6.
9. Swisher SG, Wynn P, Putnam JB, Mosheim MB, Correa AM, Komaki RR, et al.
Salvage esophagectomy for recurrent tumors after definitive chemotherapy
and radiotherapy. J Thorac Cardiovasc Surg. 2002;123:175–83.
10. Tachimori Y, Kanamori N, Uemura N, Hokamura N, Igaki H, Kato H. Salvage
esophagectomy after high-dose chemoradiotherapy for esophageal
squamous cell carcinoma. J Thorac Cardiovasc Surg. 2009;137:49–54.
11. Onozawa M, Nihei K, Ishikura S, Minashi K, Yano T, Muto M, et al. Elective
nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous
cell carcinoma of the thoracic esophagus. Radiother Oncol. 2009;92:266–9.
12. Yano T, Muto M, Hattori S, Minashi K, Onozawa M, Nihei K, et al. Long-term
results of salvage endoscopic mucosal resection in patients with local
failure after definitive chemoradiotherapy for esophageal squamous cell
carcinoma. Endoscopy. 2008;40:717–21.
13. Yano T, Muto M, Minashi K, Onozawa M, Nihei K, Ishikura S, et al. Long-term
results of salvage photodynamic therapy for patients with local failure after
chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy.
2011;43:657–63.
14. Sobin LH, Wittekind C. TNM classification of malignant tumors. 6th ed. New
York: Wiley-Liss; 2002.
15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al.
New response evaluation criteria in solid tumours: revised RECIST guideline
(version 1.1). Eur J Cancer. 2009;45:228–47.
16. Sibille A, Lambert R, Souquet JC, Sabben G, Descos F. Long-term survival
after photodynamic therapy for esophageal cancer. Gastroenterology. 1995;
108:337–44.
17. Momma K, Sasaki N, Yoshida M. Endoscopic mucosectomy for precise
evaluation and treatment of esophageal intraepithelial cancer. Endosc Dig.
1990;2:501–6.
18. Liu M, Shi X, Guo X, Yao W, Liu Y, Zhao K, et al. Long-term outcome of
irradiation with or without chemotherapy for esophageal squamous cell
carcinoma: a final report on a prospective trial. Radiat Oncol. 2012;7:142.
19. Yamashita H, Omori M, Takenaka R, Okuma K, Kobayashi R, Ohtomo K, et al.
Involved-field irradiation concurrently combined with nedaplatin/5-
fluorouracil for inoperable esophageal cancer on basis of (18)FDG-PET scans:
a phase II study. Radiother Oncol. 2014;113:182–7.
20. Esaki M, Matsumoto T, Hirakawa K, Nakamura S, Umeno J, Koga H, et al. Risk
factors for local recurrence of superficial esophageal cancer after treatment
by endoscopic mucosal resection. Endoscopy. 2007;39:41–5.
21. Katada C, Muto M, Manabe T, Ohtsu A, Yoshida S. Local recurrence of
squamous-cell carcinoma of the esophagus after EMR. Gastrointest Endosc.
2005;61:219–25.
22. Tomimaru Y, Yano M, Takachi K, Miyashiro I, Ishihara R, Nishiyama K, et al.
Factors affecting the prognosis of patients with esophageal cancer
undergoing salvage surgery after definitive chemoradiotherapy. J Surg
Oncol. 2006;93:422–8.
23. Yano T, Muto M, Minashi K, Iwasaki J, Kojima T, Fuse N, et al. Photodynamic
therapy as salvage treatment for local failure after chemoradiotherapy in
patients with esophageal squamous cell carcinoma: a phase II study. Int J
Cancer. 2012;131:1228–34.
24. Yano T, Muto M, Yoshimura K, Niimi M, Ezoe Y, Yoda Y, et al. Phase I study
of photodynamic therapy using talaporfin sodium and diode laser for local
failure after chemoradiotherapy for esophageal cancer. Radiat Oncol.
2012;7:113.
25. Griffin JM, Reed CE, Denlinger CE. Utility of restaging endoscopic ultrasound
after neoadjuvant therapy for esophageal cancer. Ann Thorac Surg. 2012;93:
1855–9. discussion 1860.
26. Hattori S, Muto M, Ohtsu A, Boku N, Manabe T, Doi T, et al. EMR as salvage
treatment for patients with locoregional failure of definitive chemoradiotherapy
for esophageal cancer. Gastrointest Endosc. 2003;58:65–70.
27. Saito Y, Takisawa H, Suzuki H, Takizawa K, Yokoi C, Nonaka S, et al. Endoscopic
submucosal dissection of recurrent or residual superficial esophageal cancer
after chemoradiotherapy. Gastrointest Endosc. 2008;67:355–9.
28. Takeuchi M, Kobayashi M, Hashimoto S, Mizuno K, Kawaguchi G, Sasamoto
R, et al. Salvage endoscopic submucosal dissection in patients with local
failure after chemoradiotherapy for esophageal squamous cell carcinoma.
Scand J Gastroenterol. 2013;48:1095–101.
29. Koizumi S, Jin M, Matsuhashi T, Tawaraya S, Watanabe N, Sawaguchi M,
et al. Salvage endoscopic submucosal dissection for the esophagus-
localized recurrence of esophageal squamous cell cancer after definitive
chemoradiotherapy. Gastrointest Endosc. 2014;79:348–53.
30. Ishihara R, Iishi H, Uedo N, Takeuchi Y, Yamamoto S, Yamada T, et al.
Comparison of EMR and endoscopic submucosal dissection for en bloc
resection of early esophageal cancers in Japan. Gastrointest Endosc. 2008;
68:1066–72.
31. Ono S, Fujishiro M, Niimi K, Goto O, Kodashima S, Yamamichi N, et al.
Long-term outcomes of endoscopic submucosal dissection for
superficial esophageal squamous cell neoplasms. Gastrointest Endosc.
2009;70:860–6.
32. Tang B, Bai JY, Zhao XY, Fan CQ, Yang X, Deng L, et al. Endoscopic submucosal
dissection for superficial esophageal cancer with near-circumferential lesions:
our experience with 40 patients. Surg Endosc. 2015;29:2141–8.
Hatogai et al. Radiation Oncology  (2016) 11:31 Page 10 of 10
